BridgeBio Oncology Therapeutics (BBOT) Other financing activities (2024 - 2026)
BridgeBio Oncology Therapeutics (BBOT) posted Other financing activities of $416000.0 for Q1 2026, down 99.89% sequentially from $373.5 million in Q4 2025.
BridgeBio Oncology Therapeutics (BBOT) Other financing activities (2024 - 2026) Analysis & Trends
BridgeBio Oncology Therapeutics has reported Other financing activities for 3 years, with the latest figure at $416000.0 in Q1 2026.
- Quarterly Other financing activities changed N/A year-over-year to $416000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $373.9 million (up 7521.06% YoY) and the FY2025 annual result came in at $373.5 million, up 718086.54% from the prior year.
- Other financing activities fell to $416000.0 in Q1 2026 per BBOT's latest filing, from $373.5 million in the prior quarter.
- Over five years, Other financing activities peaked at $373.5 million in Q4 2025 and troughed at -$5.1 million in Q3 2025.
- A 3-year average of $53.4 million and a median of $416000.0 in 2026 frame the typical range for Other financing activities.
- The widest YoY moves for Other financing activities: up 37075.94% in 2025, down 26.37% in 2025.
- Over 3 years, Other financing activities stood at -$1.0 million in 2024, then jumped by 37075.94% to $373.5 million in 2025, then plunged by 99.89% to $416000.0 in 2026.
- According to Business Quant data, Other financing activities over the past three periods registered $416000.0, $373.5 million, and -$5.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | BridgeBio Oncology Therapeutics | 726.38 Mn | 500.67 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 37,000.00 |
| Jun 30, 2026 | 37,000.00 |
| Mar 31, 2026 | 416,000.00 |
| Mar 31, 2026 | 416,000.00 |
| Dec 31, 2025 | 373.46 Mn |
| Dec 31, 2025 | 373.46 Mn |
| Sep 30, 2025 | -5.09 Mn |
| Sep 30, 2025 | -5.09 Mn |
| Jun 30, 2025 | 5.09 Mn |
| Jun 30, 2025 | 5.09 Mn |
| Dec 31, 2024 | -1.01 Mn |
| Dec 31, 2024 | -1.01 Mn |
| Sep 30, 2024 | -4.03 Mn |
| Sep 30, 2024 | -4.03 Mn |
| Mar 31, 2024 | 5.09 Mn |
| Mar 31, 2024 | 5.09 Mn |